Key facts
- Anodyne Nanotech’s last known valuation is $7.0M (Aug 2020).
- It has raised $9.6M across 3 recorded rounds; the latest was Early Stage VC ($12.6M) in May 2026.
- Notable investors include Bantam Group, Endeavor Greece, Big Pi Ventures, New Ventures Pitch Competition, Relativity Healthcare Partners — 7 tracked in total.
- Anodyne Nanotech has filed 3 Form Ds with the SEC since 2020, most recently May 2021 ($2.0M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Anodyne Nanotech
Funding rounds
3 roundsAbout Anodyne Nanotech
Developer of transdermal drug delivery technology designed to reformulate clinically validated molecules into needle-free therapeutics for chronic diseases. The company offers a patch-based platform licensed from Tufts University capable of delivering multi-milligram doses of biologics, enabling patients with obesity and related conditions to access alternatives to injectables and infusions while expanding treatment possibilities through combination therapies.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 20
- Website
- theheropatch.com/
- Ownership
- Privately Held (backing)
Anodyne Nanotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anodyne Nanotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anodyne Nanotech in its N-PORT filings yet. We sweep new filings monthly.